* eFFECTOR Therapeutics Inc EFTR.OQ EFTR.O is expected
to show
no change in quarterly revenue when it reports results on May 7
(estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for eFFECTOR Therapeutics
Inc is
for a loss of $2.16 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 24.9%
in the last three months.
* Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $11.00, above its last closing price
of $2.16.
This summary was machine generated May 3 at 11:56 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)